Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $330,853.60 in Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) CFO Avraham Gabay sold 73,360 shares of Oramed Pharmaceuticals stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total value of $330,853.60. Following the sale, the chief financial officer directly owned 671,785 shares of the company’s stock, valued at approximately $3,029,750.35. The trade was a 9.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ ORMP opened at $4.60 on Friday. Oramed Pharmaceuticals Inc. has a one year low of $1.98 and a one year high of $5.19. The business’s 50-day moving average price is $4.11 and its two-hundred day moving average price is $3.63. The company has a market capitalization of $188.28 million, a P/E ratio of 1.78 and a beta of 1.21.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 11th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Oramed Pharmaceuticals currently has an average rating of “Hold”.

Institutional Trading of Oramed Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. SB Capital Management Inc acquired a new position in Oramed Pharmaceuticals in the 4th quarter valued at $5,415,000. Marshall Wace LLP bought a new stake in Oramed Pharmaceuticals during the fourth quarter valued at about $738,000. Dimensional Fund Advisors LP boosted its holdings in Oramed Pharmaceuticals by 5.1% during the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after acquiring an additional 7,738 shares during the period. Ritholtz Wealth Management acquired a new stake in shares of Oramed Pharmaceuticals in the first quarter valued at about $529,000. Finally, Bank of America Corp DE grew its position in shares of Oramed Pharmaceuticals by 4.4% in the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 6,261 shares during the last quarter. 12.73% of the stock is currently owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.